1/9
08:02 am
anik
Anika Therapeutics (NASDAQ:ANIK) had its "outperform" rating reaffirmed by analysts at Barrington Research. They now have a $16.00 price target on the stock.
Low
Report
Anika Therapeutics (NASDAQ:ANIK) had its "outperform" rating reaffirmed by analysts at Barrington Research. They now have a $16.00 price target on the stock.
1/8
07:05 pm
anik
Anika Therapeutics Announces Leadership Transition [Yahoo! Finance]
Low
Report
Anika Therapeutics Announces Leadership Transition [Yahoo! Finance]
1/8
07:00 am
anik
Anika Therapeutics Announces Leadership Transition
Low
Report
Anika Therapeutics Announces Leadership Transition
12/30
06:00 pm
anik
ANIK Investigation: Investors Encouraged to Contact Kirby McInerney LLP
Low
Report
ANIK Investigation: Investors Encouraged to Contact Kirby McInerney LLP
12/5
08:00 pm
anik
Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors ANIK
Low
Report
Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors ANIK
12/3
05:37 am
anik
Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 39%? [Yahoo! Finance]
Low
Report
Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 39%? [Yahoo! Finance]
11/26
02:01 pm
anik
Anika Therapeutics (NASDAQ:ANIK) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Anika Therapeutics (NASDAQ:ANIK) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/6
03:47 pm
anik
Anika Therapeutics (NASDAQ:ANIK) had its price target raised by analysts at Barrington Research from $15.00 to $16.00. They now have an "outperform" rating on the stock.
Low
Report
Anika Therapeutics (NASDAQ:ANIK) had its price target raised by analysts at Barrington Research from $15.00 to $16.00. They now have an "outperform" rating on the stock.
11/5
07:05 am
anik
Anika Reports Third Quarter 2025 Financial Results
Medium
Report
Anika Reports Third Quarter 2025 Financial Results
11/5
07:00 am
anik
Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study
High
Report
Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study
10/30
12:25 pm
anik
Anika Therapeutics (NASDAQ:ANIK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Anika Therapeutics (NASDAQ:ANIK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/23
04:01 pm
anik
Anika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025
Medium
Report
Anika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025